Theravance Biopharma, Inc.

TBPH

KYG8807B1068

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
9.12 ^USD	+0.22%		-2.88%	-18.86%

May. 13	Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours	MT
May. 13	Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024

Theravance Biopharma, Inc. Announces Directorate Change

April 13, 2021 at 10:36 am EDT

Theravance Biopharma, Inc. announced the following changes to the Board of Directors of the Company: Peter Ringrose ceased to be a director on 28 April 2020; Deepika Pakianathan was appointed as director on 1 July 2020.

Latest news about Theravance Biopharma, Inc.

Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours	May. 13	MT
Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, vs. Street Est of $14M	May. 13	MT
Theravance Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Sector Update: Health Care Stocks Lower Friday Afternoon	Apr. 12	MT
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	Apr. 12	MT
BTIG Starts Theravance Biopharma With Buy Rating, $21 Price Target	Apr. 12	MT
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	Mar. 01	CI
Transcript : Theravance Biopharma, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	Feb. 26	MT
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	Jan. 05	MT
Top Premarket Decliners	Jan. 05	MT
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease	Jan. 05	CI
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.	Dec. 31	CI
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors	Dec. 21	CI
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director	Dec. 21	CI
Viatris, Theravance Biopharma Say Trial in China Shows Efficacy, Safety of COPD Treatment	Nov. 13	MT
Transcript : Theravance Biopharma, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	Nov. 07	CI
Earnings Flash (TBPH) THERAVANCE BIOPHARMA US Reports Q3 Revenue $15.7M, vs. Street Est of $15.1M	Nov. 07	MT
Theravance Biopharma, Inc. Announces Board Changes	Nov. 07	CI
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri	23-10-30	DJ
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders	23-08-28	CI

Chart Theravance Biopharma, Inc.

Duration

Period

More charts

Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Investor Meeting - Key Openion Leader

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Theravance Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.12 USD

Average target price

15.4 USD

Spread / Average Target

+68.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
THERAVANCE BIOPHARMA, INC.	-18.86%	444M
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+32.82%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.64%	244B
ROCHE HOLDING AG	-4.13%	208B
NOVARTIS AG	+10.63%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals